Is Trupanion (TRUP) overvalued or fairly valued?

MarketChacha shows Trupanion's valuation in context — a trailing P/E of about 46.1, a forward P/E of about 6.7, a price-to-book of about 3.1 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Trupanion's revenue?

Trupanion reported revenue of $1.4B for FY2025, per official filings.

What is the share price of Trupanion (TRUP)?

Trupanion last traded at $28.58 (+3.9% on the day), as of 10/20/2026 — a delayed quote shown for education, not investment advice.

Trupanion

TRUP · NYSE · Financials · United States

Snapshot

TickerTRUP

ExchangeNYSE

SectorFinancials

IndustryInsurance - Property & Casualty

CountryUnited States

Employees1,121

HeadquartersSeattle, United States

Websitewww.trupanion.com

Filings tracked13

About Trupanion

Trupanion, Inc., together with its subsidiaries, provides medical insurance for cats and dogs on subscription basis in the United States, Canada, and Continental Europe. The company operates in two segments, Subscription Business and Other Business. It serves pet owners and veterinarians. The company was formerly known as Vetinsurance International, Inc. and changed its name to Trupanion, Inc. in 2013. Trupanion, Inc. was founded in 2000 and is headquartered in Seattle, Washington.

Who owns it

Insiders15.7%
Institutions78.9%
Public & other5.4%

282 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.12.40%
Capital World Investors8.75%
AFLAC Inc.8.29%
Vanguard Portfolio Management LLC4.11%
Polar Capital Holdings PLC3.99%
Vanguard Capital Management LLC3.39%
State Street Corporation3.11%
FMR, LLC2.37%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Operating margin trend-3.7% → 1.0%

Margin has expanded by about 4.6 points — the business is getting more profitable.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $412.1M · EPS 1.12

Next fiscal year

Rev $1.7B · EPS 4.26

Est. earnings growth +5.5%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$1.4B

Revenue CAGR (2y)

+13.9%

EPS (FY2025)

0.45

Ask MarketChacha about TRUP

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	EPS
FY2025	$1.4B	0.45
FY2024	$1.3B	-0.23
FY2023	$1.1B	-1.08

Quarterly

Period	Revenue	EPS
2026Q2	$392.9M	0.16
2026Q1	$384.0M	0.11
2025Q3	$366.9M	0.13
2025Q2	$353.6M	0.22
2025Q1	$342.0M	-0.03
2024Q3	$327.5M	0.03
2024Q2	$314.8M	-0.14
2024Q1	$306.1M	-0.16
2023Q3	$285.9M	-0.10
2023Q2	$270.6M	-0.33
2023Q1	$256.3M	-0.60

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Results of operations, Other events, Exhibits
SEC8/5/2026material
10-Q filing
SEC8/5/2026
8-K — Shareholder vote results
SEC6/15/2026material
10-Q filing
SEC4/30/2026
8-K — Results of operations, Exhibits
SEC4/30/2026material
8-K — Executive/director change, Reg FD disclosure
SEC4/27/2026material
10-K filing
SEC2/13/2026
8-K — Results of operations, Exhibits
SEC2/12/2026material

2025

8-K — Material agreement, Termination of agreement, Results of operations, Material financial obligation, Exhibits
SEC11/6/2025material
10-Q filing
SEC11/6/2025
8-K — Executive/director change, Exhibits
SEC10/30/2025material
8-K — Results of operations
SEC8/7/2025material
10-Q filing
SEC8/7/2025

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.